Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Apremilast in Pediatric Moderate to Severe Plaque Psoriasis (SPROUT)
NCT03701763Phase 3Completed
- Sponsor
- Amgen
- Start
- Dec 2018
- Primary completion
- Apr 2022
- Modality
- Small Molecules
- Countries
- 10
01
Overview
Phase 3, randomised, double-blind trial in plaque psoriasis comparing Apremilast with Placebo (2 arms). Primary endpoint: Static Physician Global Assessment Response at 16 weeks. Started Dec 2018; status: completed.
02
Drugs
apremilast
03
Conditions
plaque psoriasis
Beyond the preview
Go deeper on NCT03701763.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT03701763.